ABSTRACT
Naratriptan is metabolized by several different cytochrome P450 isoenzymes in the liver to a number of inactive metabolites. The renal clearance of naratriptan exceeds the glomerular filtration rate, indicating that it is subject to active tubular secretion. Adverse drug reactions associated with naratriptan pharmacotherapy generally are transient and self-limiting. Naratriptan pharmacotherapy commonly has been associated with: dizziness, drowsiness, fatigue, malaise, nausea, and neck stiffness. Adverse drug reactions associated with naratriptan pharmacotherapy generally are transient and self-limiting. Naratriptan pharmacotherapy commonly has been associated with: dizziness, drowsiness, fatigue, malaise, nausea, and neck stiffness. In the absence of such data, naratriptan overdosage should be treated as a medical emergency requiring symptomatic support of body systems with attention to increasing naratriptan elimination. Concurrent oral contraceptive pharmacotherapy reduces both the total body clearance and the apparent volume of distribution of naratriptan resulting in a corresponding increase in naratriptan blood concentrations.
